Alirocumab post-acute coronary syndrome: An integrative review on treatment and its influence on future cardiovascular and metabolic complications
DOI:
https://doi.org/10.33448/rsd-v14i1.47973Keywords:
Alirocumab, Acute coronary syndrome, Treatment, Metabolic changes.Abstract
Acute Coronary Syndrome (ACS) is a serious condition resulting from obstruction of blood flow in the coronary arteries and it is one of the main causes of cardiovascular morbidity and mortality, especially among adults and the elderly, in whom non-traditional risk factors are more prevalent. This integrative review article aims to explore the clinical characteristics, specific risk factors, and related health outcomes after ACS in treatment with Alirocumab to offer a broad and well-founded view on the subject, directing new perspectives for improving the treatment and control of symptoms and recurrences. The review selected articles published between 2020 and 2024 in the PubMed, Scielo, and Google Scholar databases. The results show that alirocumab significantly reduces LDL-C, lipoprotein(a), and apoB levels, reducing the risk of major cardiovascular events (MACE) by up to 15%. Furthermore, the benefits were more pronounced in patients with multiple metabolic risk factors. The discussion reinforces the importance of more rigorous lipid management goals and suggests that alirocumab can be integrated into personalized therapeutic strategies, especially for patients with higher residual cardiovascular risk. It is concluded that alirocumab plays a central role in post-ACS management, standing out for its multidimensional approach and the potential to reduce cardiovascular complications in diverse populations.
Downloads
References
Alonso, M. F., Kuranishi, M. E., de Medeiros, C. T. M., Borges, L. R. S., da Silva, M. E. P., Donzelli, R. V., & Sant'Ana, P. G. (2024). Síndrome coronariana aguda em pacientes jovens: revisão de literatura. Peer Review, 6(15), 182-196.
Andersson, C., & Vasan, R. S. (2020). Epidemiology of cardiovascular disease in young individuals. Nature Reviews Cardiology, 17(4), 230-240. https://doi.org/10.1038/s41569-019-0309-9.
Anima. (2014). Manual revisão bibliográfica sistemática integrativa: a pesquisa baseada em evidências. Grupo Anima. https://biblioteca.cofen.gov.br/wp-content/uploads/2019/06/manual_revisao_bibliografica-sistematica-integrativa.pdf.
Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., & Schwartz, G. G. (2020). Effect of alirocumab on lipoprotein (a) and cardiovascular risk after acute coronary syndrome. Journal of the American College of Cardiology, 75(2), 133-144.
Crossetti, M. G. M. (2012). Revisión integradora de la investigación en enfermería el rigor científico que se le exige. Rev. Gaúcha Enferm. 33 (2): 8-9.
Gupta, A., Smith, D. A., & Bozkurt, B. (2019). Acute coronary syndrome in young adults: Current perspectives and novel concepts. Current Cardiology Reports, 21(9), 73. https://doi.org/10.1007/s11886-019-1176-5.
Haddaway, N. R., Page, M. J., Pritchard, C. C., & McGuinness, L. A. (2022). PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis Campbell Systematic Reviews, 18, e1230.
Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., ... & Schwartz, G. G. (2022). Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab. Circulation, 146(9), 657-672.
Libby, P., Loscalzo, J., Ridker, P. M., & Fuster, V. (2019). Inflammation, immunity, and infection in atherothrombosis. Journal of the American College of Cardiology, 74(4), 510-524. https://doi.org/10.1016/j.jacc.2019.05.030.
Mattos, P. C. (2015). Tipos de revisão de literatura. Unesp, 1-9. https://www.fca.unesp.br/Home/Biblioteca/tipos-de-evisao-de-literatura.pdf.
Mehta, L. S., Beckie, T. M., DeVon, H. A., Grines, C. L., Krumholz, H. M., Johnson, M. N., Lindley, K. J., Vaccarino, V., & Wang, T. Y. (2018). Acute myocardial infarction in women: A scientific statement from the American Heart Association. Circulation, 137(8), e29-e306. https://doi.org/10.1161/CIR.0000000000000619.
Ostadal, P., Steg, P. G., Poulouin, Y., Bhatt, D. L., Bittner, V. A., Chua, T., ... & Schwartz, G. G. (2022). Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet Diabetes & Endocrinology, 10(5), 330-340.
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Editora UAB/NTE/UFSM.
Pineda, A. M., Lopez, J. R., & Bradley, E. (2018). Risk factors for young adults with myocardial infarction and the need for targeted prevention. European Heart Journal - Acute Cardiovascular Care, 7(6), 591-595. https://doi.org/10.1177/2048872617747337.
Rallidis, L. S., Pavlakis, G., & Tsirebolos, G. (2019). Characteristics and cardiovascular risk factors of young patients with myocardial infarction. Journal of Cardiology, 74(2), 97-102. https://doi.org/10.1016/j.jjcc.2019.02.009.
Schwartz, G. G., Gabriel Steg, P., Bhatt, D. L., Bittner, V. A., Diaz, R., Goodman, S. G., & ODYSSEY OUTCOMES Committees and Investigators. (2021). Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score–Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation, 143(11), 1109-1122.
Schwartz, G. G., Steg, P. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., & ODYSSEY OUTCOMES Committees and Investigators*. (2020). Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein (a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, 141(20), 1608-1617.
Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., & Morrow, D. A. (2018). Fourth universal definition of myocardial infarction. Journal of the American College of Cardiology, 72(18), 2231-2264. https://doi.org/10.1016/j.jacc.2018.08.1038
Timmis, A., Townsend, N., Gale, C. P., Torbica, A., Lettino, M., Petersen, S. E., Mossialos, E., Maggioni, A. P., & Casadei, B. (2017). European Society of Cardiology: Cardiovascular disease statistics 2017. European Heart Journal, 39(7), 508-579. https://doi.org/10.1093/eurheartj/ehx628.
Wong, C. W., Kwok, C. S., Narain, A., Gulati, M., Mihalidou, A. S., & Mamas, M. A. (2020). Acute myocardial infarction in young adults – A review of aetiology, risk factors and outcomes. Postgraduate Medical Journal, 96(1132), 494-499. https://doi.org/10.1136/postgradmedj-2019-137778.
World Health Organization. (2021). Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases
Zahger, D., Schwartz, G. G., Du, W., Szarek, M., Bhatt, D. L., Bittner, V. A., & ODYSSEY OUTCOMES Investigators. (2024). Triglyceride levels, alirocumab treatment, and cardiovascular outcomes after an acute coronary syndrome. Journal of the American College of Cardiology, 84(11), 994-1006.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Carlos Eduardo do Carmo Almeida; Bruna Casati; Luana Favoreto Zanetti; Maria Clara Abreu Ventury
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
